Vicore Pharma Holding AB (DE:6Y4)
FRANKFURT:6Y4
Want to see DE:6Y4 full AI Analyst Report?
Total Valuation
Vicore Pharma Holding AB has a market cap or net worth of €282.18M. The enterprise value is €2.47B.
Market Cap€282.18M
Enterprise Value€2.47B
Share Statistics
Vicore Pharma Holding AB has 281,525,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding281,525,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Vicore Pharma Holding AB’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -41.26%.
Return on Equity (ROE)-0.44
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-41.26%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee115.67K
Profits Per Employee-14.47M
Employee Count33
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vicore Pharma Holding AB is ―. Vicore Pharma Holding AB’s PEG ratio is -0.03.
PE Ratio―
PS Ratio710.16
PB Ratio2.47
Price to Fair Value2.47
Price to FCF0.00
Price to Operating Cash Flow-8.57
PEG Ratio-0.03
Income Statement
In the last 12 months, Vicore Pharma Holding AB had revenue of 3.82M and earned -477.47M in profits. Earnings per share was -1.99.
Revenue3.82M
Gross Profit3.82M
Operating Income-454.44M
Pretax Income-477.47M
Net Income-477.47M
EBITDA-454.44M
Earnings Per Share (EPS)-1.99
Cash Flow
In the last 12 months, operating cash flow was -305.57M and capital expenditures 199.12M, giving a free cash flow of -106.45M billion.
Operating Cash Flow-305.57M
Free Cash Flow-106.45M
Free Cash Flow per Share-0.38
Dividends & Yields
Vicore Pharma Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.37
52-Week Price Change32.78%
50-Day Moving Average0.90
200-Day Moving Average0.96
Relative Strength Index (RSI)55.28
Average Volume (3m)0.00
Important Dates
Vicore Pharma Holding AB upcoming earnings date is Aug 21, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
Vicore Pharma Holding AB as a current ratio of 10.31, with Debt / Equity ratio of 0.00%
Current Ratio10.31
Quick Ratio10.31
Debt to Market Cap0.00
Net Debt to EBITDA1.27
Interest Coverage Ratio-9.03
Taxes
In the past 12 months, Vicore Pharma Holding AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vicore Pharma Holding AB EV to EBITDA ratio is -4.69, with an EV/FCF ratio of 0.00.
EV to Sales558.69
EV to EBITDA-4.69
EV to Free Cash Flow0.00
EV to Operating Cash Flow-5.70
Balance Sheet
Vicore Pharma Holding AB has €1.06B in cash and marketable securities with €0.00 in debt, giving a net cash position of €1.06B billion.
Cash & Marketable Securities€1.06B
Total Debt€0.00
Net Cash€1.06B
Net Cash Per Share€3.76
Tangible Book Value Per Share€4.57
Margins
Gross margin is 78.45%, with operating margin of -11905.82%, and net profit margin of -12509.14%.
Gross Margin78.45%
Operating Margin-11905.82%
Pretax Margin-12509.14%
Net Profit Margin-12509.14%
EBITDA Margin-11905.82%
EBIT Margin-11905.82%
Analyst Forecast
The average price target for Vicore Pharma Holding AB is €3.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€3.49
Price Target Upside279.81% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-38.41%
EPS Growth Forecast-4.71%